Barclays
XBIT icon

Barclays’s XBiotech XBIT Stock Holding History

Barclays’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$2 – 5486
2025
Q4 		$2 Sell
1
-206
-100% -$508 ﹤0.01% 5186
2025
Q3 		$551 Buy
207
+206
+20,600% +$610 ﹤0.01% 5202
2025
Q2 		$3 Sell
1
-20,107
-100% -$58.5K ﹤0.01% 5180
2025
Q1 		$65.2K Sell
20,108
-9,896
-33% -$34.1K ﹤0.01% 4542
2024
Q4 		$119K Buy
30,004
+3,661
+14% +$25K ﹤0.01% 4555
2024
Q3 		$204K Buy
26,343
+18,761
+247% +$123K ﹤0.01% 4271
2024
Q2 		$39K Buy
+7,582
New +$58.5K ﹤0.01% 4301
2022
Q2 		– Sell
-2,563
Closed -$23K – 5296
2022
Q1 		$23K Sell
2,563
-15,921
-86% -$160K ﹤0.01% 4409
2021
Q4 		$206K Buy
18,484
+12,220
+195% +$159K ﹤0.01% 3557
2021
Q3 		$80K Buy
6,264
+4,256
+212% +$67.8K ﹤0.01% 3986
2021
Q2 		$34K Sell
2,008
-10,228
-84% -$173K ﹤0.01% 4319
2021
Q1 		$210K Buy
12,236
+7,424
+154% +$139K ﹤0.01% 3684
2020
Q4 		$75K Sell
4,812
-1,783
-27% -$32.9K ﹤0.01% 4250
2020
Q3 		$127K Sell
6,595
-1,300
-16% -$22.4K ﹤0.01% 4117
2020
Q2 		$108K Buy
7,895
+2,636
+50% +$37K ﹤0.01% 4463
2020
Q1 		$56K Sell
5,259
-13,807
-72% -$225K ﹤0.01% 5164
2019
Q4 		$356K Buy
19,066
+3,161
+20% +$40.7K ﹤0.01% 4571
2019
Q3 		$166K Buy
15,905
+1,728
+12% +$14.1K ﹤0.01% 5103
2019
Q2 		$108K Sell
14,177
-65,375
-82% -$569K ﹤0.01% 5634
2019
Q1 		$877K Buy
79,552
+79,544
+994,300% +$645K ﹤0.01% 3548
2018
Q4 		$0 Hold
8
– – ﹤0.01% 7390
2018
Q3 		$0 Hold
8
– – ﹤0.01% 7434
2018
Q2 		$0 Sell
8
-4,110
-100% -$18.6K ﹤0.01% 7333
2018
Q1 		$21K Buy
4,118
+17
+0.4% +$78 ﹤0.01% 6416
2017
Q4 		$16K Buy
4,101
+3,348
+445% +$14.1K ﹤0.01% 6383
2017
Q3 		$3K Buy
753
+367
+95% +$1.73K ﹤0.01% 6613
2017
Q2 		$2K Sell
386
-782
-67% -$7.49K ﹤0.01% 6450
2017
Q1 		$20K Sell
1,168
-1,056
-47% -$13.8K ﹤0.01% 5818
2016
Q4 		$23K Buy
2,224
+2,019
+985% +$26.9K ﹤0.01% 5563
2016
Q3 		$2K Sell
205
-2,494
-92% -$36.6K ﹤0.01% 6280
2016
Q2 		$57K Buy
2,699
+2,384
+757% +$34.4K ﹤0.01% 4761
2016
Q1 		$3K Sell
315
-359
-53% -$2.97K ﹤0.01% 5812
2015
Q4 		$7K Buy
+674
New +$8.61K ﹤0.01% 5500

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's XBIT Position: Q1 2026 in Review

Barclays sold out of XBiotech (XBIT) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

Barclays first reported a position in XBIT in Q4 2015 and held it in 33 quarters. The position peaked at $877K in Q1 2019. 37 funds tracked by Wall St. Rank hold XBIT as of Q1 2026.

  • Barclays reported no remaining XBiotech position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 1 XBiotech share in Q1 2026, an estimated $2.
  • Barclays first reported a position in XBiotech in Q4 2015 and held it in 33 quarters.
  • Barclays's XBiotech position peaked at $877K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held XBiotech as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.